Childhood obesity will ultimately cost someone a significant amount of money, whether it be the parents or the kids themselves when they grow up.

Most people probably do not have a clue about all the history behind the availability (or not) of water in either public locales or in places of business.

Childhood obesity in Europe is rising. Experts debate GLP-1 drugs for kids: balancing safety, access, and prevention in tackling this epidemic.

The cost that obesity imposes on society is enormous, but (no surprise here) plenty of angles remain to be explored.

The phenomenon known as “presenteeism” has grown immensely, and so has the societal expense associated with it.

New study shows Mounjaro lowers blood sugar and BMI in kids with Type 2 diabetes, paving the way for FDA approval in younger patients.

WHO adds semaglutide and tirzepatide to essential medicines, aiming to lower costs and expand global access to diabetes and obesity care.

The presenteeism-related financial damage caused by obesity will not eventually subside, and the effect will only become more severe.

The term “presenteeism” is loaded with much more significance than merely showing up. Let’s dive in.

Yale study finds 20–40% of obesity-related conditions in U.S. youth are tied to obesity, highlighting the importance of early prevention and treatment.

How much does obesity cost the overall economy, anyway? This sounds like a trick question, because it is.

Doctors emphasize lifestyle changes first in obesity care, even with GLP-1 drugs. Learn why combining medication with therapy drives lasting results.

The weight factor’s ubiquity and banality place it in danger of being overlooked and undervalued, but paying meticulous attention to this issue is important.

In the field of bariatrics, it seems obvious that heavy people face physical challenges and restrictions that can require some pretty elaborate equipment.

A new brain-targeted obesity drug may offer weight loss without GLP-1 side effects, using support cells to curb appetite and improve glucose control.

And looking at a bit of specialized bariatric equipment, and the associated prices, hopefully will cause some degree of a “scared straight” effect.

New research reveals that approximately 17 million adolescents and young adults in the U.S. meet the criteria for GLP-1RA therapy, but it’s complicated.

A new study using genetic data from over 5 million people has developed a powerful polygenic risk score that predicts childhood obesity risk.

Today, we know that weight is influenced by a combination of factors, including genetics, socioeconomic status, mental health, stress, environment, and sleep.

It’s increasingly vital to know how each childhood obesity program works, how much it costs, and how much it is likely to cost moving forward.

New study: Prenatal and early-life conditions significantly shape a child’s risk for obesity later in life.

The topic of money and the subject of obesity impinge upon each other quite extensively.

Exploring the psychological and social impacts of using GLP-1 drugs for weight loss.

A clinical trial showed that this monthly injection could change the game, especially for those who struggle with weekly dosing.

In his interview with the Los Angeles Times, former FDA Commissioner Dr. David A. Kessler summarizes the science of weight loss.

It is possible to encourage one’s personal stock of the helpful bacterium by eating its favorite foods, like high-fiber vegetation and nondigestible carbs.

The mucus-loving bacterium Akkermansia muciniphila offers a glimpse of an exciting future of drug-free therapy that achieves sustainable weight loss.

Despite the long-term nature of obesity, current clinical guidelines are usually split into rigid age categories. Some experts say it needs to change.

We really need to know what the substances are doing to our kids (and us). Does a certain ingredient make children obese?

The MAHA Report: Make Our Children Healthy Again sparks criticism over its priorities and scientific validity.